StockData
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31

Tilray Brands, Inc.

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$3.03−0.01 (-0.33%)

Close on Oct 19, 2026

Market cap
$404.02M
P/E (TTM)
–
Dividend yield
–

Tilray Brands, Inc. revenue by segment

By business segment

RevenueTTM Q4 26TTM Q3 26TTM Q2 26TTM Q1 26TTM Q4 25TTM Q3 25TTM Q2 25TTM Q1 25TTM Q4 24TTM Q3 24TTM Q2 24TTM Q1 24% of revenueYoY
Distribution Business [Member]$327.24M$316.34M$294.87M$277.16M$271.23M$262.74M$258.04M$257.65M$258.74M$265.79M$274.38M$267.34M35.7%+20.7%
Cannabis Segment [Member]$268.34M$264.70M$254.14M$252.26M$249.00M$253.09M$262.25M$263.71M$272.80M$265.29M$249.41M$232.19M29.3%+7.8%
Beverage Alcohol Business [Member]$253.98M$214.00M$227.36M$240.36M$240.60M$251.71M$250.48M$233.90M$202.09M$157.76M$123.71M$98.60M27.7%+5.6%
Wellness Business [Member]$65.89M$63.24M$60.95M$60.98M$60.49M$59.11M$58.44M$56.77M$55.31M$54.41M$53.00M$52.73M7.2%+8.9%
Tilray Pharma Segment [Member]––––––––$258.74M–––––

By product or service

By region

RevenueTTM Q4 26TTM Q3 26TTM Q2 26TTM Q1 26TTM Q4 25TTM Q3 25TTM Q2 25TTM Q1 25TTM Q4 24TTM Q3 24TTM Q2 24TTM Q1 24% of revenueYoY
EMEA [Member]$445.70M$387.40M$354.83M$330.93M$323.35M$303.62M$298.38M$294.42M$296.45M$306.84M$310.81M$298.23M48.7%+37.8%
United States$242.39M$247.12M$259.86M$273.78M$273.70M$285.95M$283.91M$265.53M$233.14M–––26.5%-11.4%
Canada$215.66M$214.87M$212.58M$215.12M$212.86M$223.86M$233.07M$237.60M$243.72M–––23.6%+1.3%
Rest of World [Member]$11.71M$8.88M$10.06M$10.94M$11.40M$13.23M$13.86M$14.49M$15.63M$14.97M$15.31M$16.66M1.3%+2.6%
North America [Member]–––––––––$421.44M$374.38M$335.97M––

From the segment and revenue-disaggregation notes of Tilray Brands's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.